| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.06▼ | 1.06▼ | 1.06▼ | 1.05▼ | 1.10▼ |
| MA10 | 1.08▼ | 1.08▼ | 1.09▼ | 1.10▼ | 1.11▼ |
| MA20 | 1.13▼ | 1.14▼ | 1.16▼ | 1.12▼ | 1.11▼ |
| MA50 | 1.45▼ | N/A | N/A | 1.11▼ | N/A |
| MA100 | N/A | N/A | N/A | 1.22▼ | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | 25.427 | 16.273▼ | 9.805▼ | 17.085▼ | 49.401 |
| WILL %R | -96.667▼ | -98.864▼ | -98.864▼ | -80.000▼ | -59.480 |
| CCI | -82.976 | -82.283 | -78.587 | -101.801▼ | -99.352 |
|
Monday, July 29, 2019 05:05 AM
MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)--Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully completed its Phase ...
|
|
Monday, July 29, 2019 01:06 AM
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that it has successfully completed its Phase 1 study of PBT434, a novel, orally bioavailable small ...
|
|
Wednesday, May 08, 2019 05:00 PM
Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/11/19 | 1.01 | 1.08 | 1.01 | 1.05 | 3,800 |
| 11/11/19 | 1.01 | 1.08 | 1.01 | 1.08 | 1,700 |
| 08/11/19 | 1.05 | 1.11 | 1.01 | 1.03 | 17,000 |
| 07/11/19 | 1.09 | 1.10 | 1.05 | 1.05 | 18,900 |
| 06/11/19 | 1.05 | 1.13 | 1.05 | 1.06 | 18,900 |
| 05/11/19 | 1.08 | 1.11 | 1.0701 | 1.10 | 14,935 |
| 04/11/19 | 1.12 | 1.12 | 1.06 | 1.11 | 28,360 |
| 01/11/19 | 1.15 | 1.15 | 1.12 | 1.15 | 21,500 |
| 31/10/19 | 1.19 | 1.19 | 1.12 | 1.16 | 11,200 |
| 30/10/19 | 1.16 | 1.20 | 1.16 | 1.18 | 15,100 |
|
|
||||
|
|
||||
|
|